rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-474-483rsp-3633Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN XXI CENTURYОбновленные международные рекомендации (EULAR, 2023) по лечению псориатического артритаUpdated international recommendations (EULAR, 2023) for the treatment of psoriatic arthritishttps://orcid.org/0000-0001-5968-2403КорсаковаЮ. Л.KorsakovaYu. L.

Корсакова Юлия Леонидовна - старший научный сотрудник лаборатории спондилоартритов

115522, Москва, Каширское шоссе, 34а

Yulia Korsakova

115522, Moscow, Kashirskoye Highway, 34A

yulkorsakova@bk.ruhttps://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-3195-5187ЭрдесШ. Ф.ErdesSh.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-6875-4552ЛогиноваЕ. Ю.LoginovaE. Yu.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

119991, Москва, ул. Трубецкая, 8, стр. 2

115522, Moscow, Kashirskoye Highway, 34A

119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202431102024625474483Copyright © Корсакова Ю.Л., Коротаева Т.В., Эрдес Ш.Ф., Логинова Е.Ю., Насонов Е.Л., 20242024Корсакова Ю.Л., Коротаева Т.В., Эрдес Ш.Ф., Логинова Е.Ю., Насонов Е.Л.Korsakova Y.L., Korotaeva T.V., Erdes S., Loginova E.Y., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3633

В последние годы наблюдается значительный прогресс в изучении псориатического артрита (ПсА). Расширились возможности терапии псориаза (Пс) и ПсА. Для лечения ПсА применяют следующие лекарственные средства: традиционные синтетические базисные противовоспалительные препараты (БПВП); генно-инженерные биологические препараты, влияющие на фактор некроза опухоли, интерлейкин (ИЛ) 12/23 или ИЛ-23, а также ИЛ-17A и ИЛ-17A/F и таргетные синтетические БПВП, которые ингибируют янус-киназы или фосфодиэстеразу 4. Со времени публикации рекомендаций Европейского альянса ревматологических ассоциаций (EULAR, European Alliance of Associations for Rheumatology) по лечению ПсА 2019 г. произошли изменения, поэтому потребовалось их обновление, в котором рассматривается лечение всего спектра проявлений ПсА, включая внескелетные изменения и сопутствующие заболевания. Обновленные рекомендации включают 7 общих принципов и 11 рекомендаций. В статье представлены рекомендации EULAR 2023 г. по лечению ПсА, а также перспективные направления научных исследований. Обновленные рекомендации должны быть полезны не только клиницистам, но и пациентам при обсуждении вариантов лечения и принятии решений.

In recent years, there has been significant progress in the study of psoriatic arthritis (PsA). The possibilities of psoriasis (Ps) and PsA therapy have expanded. The following drugs are used for the treatment of PsA: conventional synthetic disease-modifying antirheumatic drugs (DMARDs); biological DMARDs targeting tumour necrosis factor (TNF), interleukin (IL) 12/23 or IL-23 pathway, and IL-17A and IL-17A/F pathway; and targeted synthetic DMARDs that inhibit Janus kinases or phosphodiesterase 4. There have been changes since the last EULAR (European Alliance of Associations for Rheumatology) recommendations for the treatment of PsA from 2019, so an update was required, which examines the treatment of the entire spectrum of PsA manifestations, including cutaneous Ps, extra-musculoskeletal manifestations and concomitant diseases. The updated recommendations include 7 general principles and 11 recommendations. The article presents the EULAR recommendations for the treatment of PsA, as well as research agenda indicating priorities for future research in PsA. The updated recommendations should be useful not only for clinicians, but also for patients when discussing treatment options and making decisions.

псориатический артритмеждународные рекомендации для лечения псориатического артритаpsoriatic arthritisinternational recommendations for the treatment of psoriatic arthritisИсследование проводилось в рамках выполнения фундаментальной научной темы «Совершенствование диагностики и фармакотерапии спондилоартритов на основании сравнительных результатов изучения (в том числе молекулярно-биологических, молекулярно-генетических, клинико-визуализационных) факторов прогрессирования заболевания и уровня качества жизни больных», утвержденной ученым советом ФГНБУ НИИР им. В.А. Насоновой (регистрационный номер темы в ЕГИСУ 1021051503111-9).ReferencesRitchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:2095-2096. doi: 10.1056/NEJMra1505557Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:2095-2096. doi: 10.1056/NEJMra1505557Pittam B, Gupta S, Harrison NL, Robertson S, Hughes DM, Zhao SS. Prevalence of extra-articular manifestations in psoriatic arthritis: A systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(9):2199-2206. doi: 10.1093/rheumatology/keaa062Pittam B, Gupta S, Harrison NL, Robertson S, Hughes DM, Zhao SS. Prevalence of extra-articular manifestations in psoriatic arthritis: A systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(9):2199-2206. doi: 10.1093/rheumatology/keaa062Корсакова ЮЛ, Логинова ЕЮ, Коротаева ТВ, Губарь ЕЕ, Глухова СИ, и др. Бремя прогрессирования псориатического артрита. Данные общероссийского регистра. Терапевтический архив. 2022;94(5):622-627.Korsakova YL, Korotaeva TV, Loginova EY, Gubar EE, Vorobyeva LD, Glukhova SI, et al. A new integral enthesial-comorbididity index of psoriatic arthritis activity. Terapevticheskii arkhiv. 2022;94(5):622-627 (In Russ.). doi: 10.26442/00403660.2022.05.201506Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706-719. doi: 10.1136/ard-2024-225531Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706-719. doi: 10.1136/ard-2024-225531Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al.; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479. doi: 10.1038/s41584-022-00798-0Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al.; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479. doi: 10.1038/s41584-022-00798-0Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Similarities and differences. Joint Bone Spine. 2023;90(1):105469. doi: 10.1016/j.jbspin.2022.105469Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Similarities and differences. Joint Bone Spine. 2023;90(1):105469. doi: 10.1016/j.jbspin.2022.105469Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162-1170. doi: 10.1136/ard-2023-224148Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162-1170. doi: 10.1136/ard-2023-224148Alharbi S, Ye JY, Lee KA, Chandran V, Cook RJ, Gladman DD. Remission in psoriatic arthritis: Definition and predictors. Semin Arthritis Rheum. 2020;50(6):1494-1499. doi: 10.1016/j.semarthrit.2020.01.012Alharbi S, Ye JY, Lee KA, Chandran V, Cook RJ, Gladman DD. Remission in psoriatic arthritis: Definition and predictors. Semin Arthritis Rheum. 2020;50(6):1494-1499. doi: 10.1016/j.semarthrit.2020.01.012Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: Lessons learned and future directions. Nat Rev Rheumatol. 2019;15(8):461-474. doi: 10.1038/s41584-019-0256-0Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: Lessons learned and future directions. Nat Rev Rheumatol. 2019;15(8):461-474. doi: 10.1038/s41584-019-0256-0Lubrano E, Scriffignano S, de Vlam K, Ronga M, Perrotta FM, Lories R. Triple jump for the optimal management of psoriatic arthritis: Diet, sleep and exercise – A review. RMD Open. 2023;9(3):e003339. doi: 10.1136/rmdopen-2023-003339Lubrano E, Scriffignano S, de Vlam K, Ronga M, Perrotta FM, Lories R. Triple jump for the optimal management of psoriatic arthritis: Diet, sleep and exercise – A review. RMD Open. 2023;9(3):e003339. doi: 10.1136/rmdopen-2023-003339Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5-32. doi: 10.1002/art.40726Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5-32. doi: 10.1002/art.40726Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, openlabel, randomised controlled trial. Lancet. 2015;386(10012):2489-2498. doi: 10.1016/S0140-6736(15)00347-5Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, openlabel, randomised controlled trial. Lancet. 2015;386(10012):2489-2498. doi: 10.1016/S0140-6736(15)00347-5Mease PJ, Coates LC. Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum. 2018;47(6):786-796. doi: 10.1016/j.semarthrit.2017.10.021Mease PJ, Coates LC. Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum. 2018;47(6):786-796. doi: 10.1016/j.semarthrit.2017.10.021Hagège B, Tan E, Gayraud M, Fautrel B, Gossec L, Mitrovic S. Remission and low disease activity in psoriatic arthritis publications: A systematic literature review with meta-analysis. Rheumatology (Oxford). 2020;59(8):1818-1825. doi: 10.1093/rheumatology/keaa030Hagège B, Tan E, Gayraud M, Fautrel B, Gossec L, Mitrovic S. Remission and low disease activity in psoriatic arthritis publications: A systematic literature review with meta-analysis. Rheumatology (Oxford). 2020;59(8):1818-1825. doi: 10.1093/rheumatology/keaa030Landewé RBM, van der Heijde D. Use of multidimensional composite scores in rheumatology: Parsimony versus subtlety. Ann Rheum Dis. 2021;80:280-285. doi: 10.1136/annrheumdis-2020-216999Landewé RBM, van der Heijde D. Use of multidimensional composite scores in rheumatology: Parsimony versus subtlety. Ann Rheum Dis. 2021;80:280-285. doi: 10.1136/annrheumdis-2020-216999Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76(4):673-680. doi: 10.1136/annrheumdis-2016-210242Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76(4):673-680. doi: 10.1136/annrheumdis-2016-210242Vincken NLA, Balak DMW, Knulst AC, Welsing PMJ, van Laar JM. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: A systematic review. Rheumatology (Oxford). 2022;61(11):4232-4244. doi: 10.1093/rheumatology/keac129Vincken NLA, Balak DMW, Knulst AC, Welsing PMJ, van Laar JM. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: A systematic review. Rheumatology (Oxford). 2022;61(11):4232-4244. doi: 10.1093/rheumatology/keac129Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34. doi: 10.1136/ard-2022-223296Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34. doi: 10.1136/ard-2022-223296Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, et al. GO-DACT: A phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020;79(4):490-498. doi: 10.1136/annrheumdis-2019-216500Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, et al. GO-DACT: A phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020;79(4):490-498. doi: 10.1136/annrheumdis-2019-216500Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: A systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760-774. doi: 10.1136/ard-2024-225534Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: A systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760-774. doi: 10.1136/ard-2024-225534Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al.; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al.; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al.; EXCEED Study Group. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-XMcInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al.; EXCEED Study Group. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-XGossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022;81(6):823-830. doi: 10.1136/annrheumdis-2021-221640Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022;81(6):823-830. doi: 10.1136/annrheumdis-2021-221640Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebocontrolled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebocontrolled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: A randomised, double-blind, placebocontrolled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38-48. doi: 10.1016/S0140-6736(22)02303-0Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: A randomised, double-blind, placebocontrolled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38-48. doi: 10.1016/S0140-6736(22)02303-0Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D’Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: Results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582-590. doi: 10.1136/annrheumdis-2020-218808Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D’Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: Results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582-590. doi: 10.1136/annrheumdis-2020-218808Helliwell PS, Gladman DD, Chakravarty SD, Kafka S, Karyekar CS, You Y, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: Pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020;6(1):e001149. doi: 10.1136/rmdopen-2019-001149Helliwell PS, Gladman DD, Chakravarty SD, Kafka S, Karyekar CS, You Y, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: Pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020;6(1):e001149. doi: 10.1136/rmdopen-2019-001149Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258-270. doi: 10.1002/art.40728Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258-270. doi: 10.1002/art.40728Mease PJ, Helliwell PS, Gladman DD, Poddubnyy D, Baraliakos X, Chakravarty SD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: A post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3(10):e715-e723. doi: 10.1016/S2665-9913(21)00105-3Mease PJ, Helliwell PS, Gladman DD, Poddubnyy D, Baraliakos X, Chakravarty SD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: A post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3(10):e715-e723. doi: 10.1016/S2665-9913(21)00105-3Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019;58(2):336-344. doi: 10.1093/rheumatology/key069Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019;58(2):336-344. doi: 10.1093/rheumatology/key069Leung YY, Eder L, Orbai AM, Coates LC, de Wit M, Smolen JS, et al. Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying indexbased and patient-based definitions of remission: A cross-sectional study. RMD Open. 2023;9(3):e003157. doi: 10.1136/rmdopen-2023-003157Leung YY, Eder L, Orbai AM, Coates LC, de Wit M, Smolen JS, et al. Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying indexbased and patient-based definitions of remission: A cross-sectional study. RMD Open. 2023;9(3):e003157. doi: 10.1136/rmdopen-2023-003157Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733Tarannum S, Leung YY, Johnson SR, Widdifield J, Strand V, Rochon P, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513-526. doi: 10.1038/s41584-022-00810-7Tarannum S, Leung YY, Johnson SR, Widdifield J, Strand V, Rochon P, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513-526. doi: 10.1038/s41584-022-00810-7Orbai AM, Perin J, Gorlier C, Coates LC, Kiltz U, Leung YY, et al. Determinants of patient-reported psoriatic arthritis impact of disease: An analysis of the association with sex in 458 patients from fourteen countries. Arthritis Care Res (Hoboken). 2020;72(12):1772-1779. doi: 10.1002/acr.24090Orbai AM, Perin J, Gorlier C, Coates LC, Kiltz U, Leung YY, et al. Determinants of patient-reported psoriatic arthritis impact of disease: An analysis of the association with sex in 458 patients from fourteen countries. Arthritis Care Res (Hoboken). 2020;72(12):1772-1779. doi: 10.1002/acr.24090Lindström U, di Giuseppe D, Exarchou S, Alenius GM, Olofsson T, Klingberg E, et al. Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: An observational nationwide study. RMD Open. 2023;9(2):e002883. doi: 10.1136/rmdopen-2022-002883Lindström U, di Giuseppe D, Exarchou S, Alenius GM, Olofsson T, Klingberg E, et al. Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: An observational nationwide study. RMD Open. 2023;9(2):e002883. doi: 10.1136/rmdopen-2022-002883Lindström U, Di Giuseppe D, Delcoigne B, Glintborg B, Möller B, Ciurea A, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheum Dis. 2021;80(11):1410-1418. doi: 10.1136/annrheumdis-2021-220097Lindström U, Di Giuseppe D, Delcoigne B, Glintborg B, Möller B, Ciurea A, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Ann Rheum Dis. 2021;80(11):1410-1418. doi: 10.1136/annrheumdis-2021-220097Behrens F, Cañete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: A systematic review of the literature. Rheumatology (Oxford). 2015;54(5):915-926. doi: 10.1093/rheumatology/keu415Behrens F, Cañete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: A systematic review of the literature. Rheumatology (Oxford). 2015;54(5):915-926. doi: 10.1093/rheumatology/keu415Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, et al.; MUST Investigator Group. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): A randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol. 2023;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, et al.; MUST Investigator Group. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): A randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol. 2023;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227-1239. doi: 10.1056/NEJMoa2022516McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227-1239. doi: 10.1056/NEJMoa2022516Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al.; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. doi: 10.1056/NEJMoa2109927Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al.; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. doi: 10.1056/NEJMoa2109927European Medicine Agency. Janus kinase inhibitors (JAKi) – referral. URL: https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki [Accessed: 7th November 2023.European Medicine Agency. Janus kinase inhibitors (JAKi) – referral. URL: https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki [Accessed: 7th November 2023.US Food and Drug Administration. Janus Kinase (JAK) inhibitors: Drug safety communication – FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. URL: https://www.fda.gov/safety/medical-productsafety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk [Accessed: 7th November 2023.US Food and Drug Administration. Janus Kinase (JAK) inhibitors: Drug safety communication – FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. URL: https://www.fda.gov/safety/medical-productsafety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk [Accessed: 7th November 2023.Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735. doi: 10.1136/rmdopen-2022-002735Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735. doi: 10.1136/rmdopen-2022-002735Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from realworld data. Ann Rheum Dis. 2020;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from realworld data. Ann Rheum Dis. 2020;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761Mease P, Gladman D, Coates L, Aelion J, Vasandani J, Kavanaugh A, et al. 16-week results from FOREMOST, a placebocontrolled study involving oligoarticular psoriatic arthritis treated with apremilast. Arthritis Rheumatol. 2023;75(Suppl 9):1691.Mease P, Gladman D, Coates L, Aelion J, Vasandani J, Kavanaugh A, et al. 16-week results from FOREMOST, a placebocontrolled study involving oligoarticular psoriatic arthritis treated with apremilast. Arthritis Rheumatol. 2023;75(Suppl 9):1691.Schett G, Lories RJ, D’Agostino MA, Elewaut D, Kirkham B, Soriano ER, et al. Enthesitis: From pathophysiology to treatment. Nat Rev Rheumatol. 2017 ;13(12):731-741. doi: 10.1038/nrrheum.2017.188Schett G, Lories RJ, D’Agostino MA, Elewaut D, Kirkham B, Soriano ER, et al. Enthesitis: From pathophysiology to treatment. Nat Rev Rheumatol. 2017 ;13(12):731-741. doi: 10.1038/nrrheum.2017.188Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, et al. The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford). 2018;57(1):32-40. doi: 10.1093/rheumatology/kex079Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, et al. The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford). 2018;57(1):32-40. doi: 10.1093/rheumatology/kex079Mulder MLM, Vriezekolk JE, van Hal TW, Nieboer LM, den Broeder N, de Jong EMGJ, et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): A double-blind, placebo-controlled, randomised, trial. Lancet Rheumatol. 2022;4(4):e252-e261. doi: 10.1016/S2665-9913(22)00028-5Mulder MLM, Vriezekolk JE, van Hal TW, Nieboer LM, den Broeder N, de Jong EMGJ, et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): A double-blind, placebo-controlled, randomised, trial. Lancet Rheumatol. 2022;4(4):e252-e261. doi: 10.1016/S2665-9913(22)00028-5Coates LC, Tillett W, D’Agostino MA, Rahman P, Behrens F, McDearmon-Blondell EL, et al. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): A randomised, open-label, two-part, phase 4 study. Lancet Rheumatol. 2022;4(4):e262-e273. doi: 10.1016/S2665-9913(22)00008-XCoates LC, Tillett W, D’Agostino MA, Rahman P, Behrens F, McDearmon-Blondell EL, et al. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): A randomised, open-label, two-part, phase 4 study. Lancet Rheumatol. 2022;4(4):e262-e273. doi: 10.1016/S2665-9913(22)00008-XOgdie A, Shin DB, Love TJ, Gelfand JM. Body surface area affected by psoriasis and the risk for psoriatic arthritis: A prospective population-based cohort study. Rheumatology (Oxford). 2022;61(5):1877-1884. doi: 10.1093/rheumatology/keab622Ogdie A, Shin DB, Love TJ, Gelfand JM. Body surface area affected by psoriasis and the risk for psoriatic arthritis: A prospective population-based cohort study. Rheumatology (Oxford). 2022;61(5):1877-1884. doi: 10.1093/rheumatology/keab622Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al.; OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552-561. doi: 10.1016/S0140-6736(14)62113-9Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al.; OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552-561. doi: 10.1016/S0140-6736(14)62113-9Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, et al. Risankizumab versus ustekinumab for moderateto-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551-1560. doi: 10.1056/NEJMoa1607017Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, et al. Risankizumab versus ustekinumab for moderateto-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551-1560. doi: 10.1056/NEJMoa1607017Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-tosevere plaque psoriasis: Results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021;185(6):1124-1134. doi: 10.1111/bjd.20413Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-tosevere plaque psoriasis: Results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021;185(6):1124-1134. doi: 10.1111/bjd.20413Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, et al.; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate- to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047-1058. doi: 10.1111/bjd.19509Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, et al.; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate- to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047-1058. doi: 10.1111/bjd.19509Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al.; UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946-1960. doi: 10.1056/NEJMoa1602773Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al.; UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946-1960. doi: 10.1056/NEJMoa1602773Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al.; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736. doi: 10.1056/NEJMoa1606910Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al.; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736. doi: 10.1056/NEJMoa1606910Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al.; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201-1214. doi: 10.1056/NEJMoa1900750Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al.; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201-1214. doi: 10.1056/NEJMoa1900750Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D’Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966-1980. doi: 10.1056/NEJMoa2212728Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D’Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966-1980. doi: 10.1056/NEJMoa2212728Letarouilly JG, Pham T, Pierache A, Acquacalda É, Banneville B, Barbarot S, et al. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: Results from the case-control MISSIL study. Rheumatology (Oxford). 2022;61(7):2848-2855. doi: 10.1093/rheumatology/keab819Letarouilly JG, Pham T, Pierache A, Acquacalda É, Banneville B, Barbarot S, et al. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: Results from the case-control MISSIL study. Rheumatology (Oxford). 2022;61(7):2848-2855. doi: 10.1093/rheumatology/keab819Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Curr Med Res Opin. 2019;35(10):1751-1759. doi: 10.1080/03007995.2019.1620713Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Curr Med Res Opin. 2019;35(10):1751-1759. doi: 10.1080/03007995.2019.1620713Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: Risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019;50(4):373-385. doi: 10.1111/apt.15397Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: Risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019;50(4):373-385. doi: 10.1111/apt.15397Ye W, Tucker LJ, Coates LC. Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs. 2018;78(16):1705-1715. doi: 10.1007/s40265-018-0994-3Ye W, Tucker LJ, Coates LC. Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs. 2018;78(16):1705-1715. doi: 10.1007/s40265-018-0994-3Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, et al.; SPIRIT-P3 Study Group. Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: Results from a randomized, double-blind withdrawal study. Arthritis Rheumatol. 2021;73(9):1663-1672. doi: 10.1002/art.41716Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, et al.; SPIRIT-P3 Study Group. Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: Results from a randomized, double-blind withdrawal study. Arthritis Rheumatol. 2021;73(9):1663-1672. doi: 10.1002/art.41716Ruwaard J, L’Ami MJ, Kneepkens EL, Krieckaert C, Nurmohamed MT, Hooijberg F, et al. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: A randomized controlled trial. Scand J Rheumatol. 2023;52(2):129-136. doi: 10.1080/03009742.2022.2028364Ruwaard J, L’Ami MJ, Kneepkens EL, Krieckaert C, Nurmohamed MT, Hooijberg F, et al. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: A randomized controlled trial. Scand J Rheumatol. 2023;52(2):129-136. doi: 10.1080/03009742.2022.2028364

The authors declare that there are no conflicts of interest present.